利拉鲁肽治疗儿童肥胖症

IF 45.9 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Nature Reviews Gastroenterology &Hepatology Pub Date : 2024-10-15 DOI:10.1038/s41575-024-01010-2

Eleni Kotsiliti

引用次数: 0

摘要

一项IIIa期试验测试了利拉鲁肽（一种胰高血糖素样肽1受体激动剂）对82名肥胖症儿童（6至12岁）的安全性和有效性。这些儿童被随机分配（2:1）接受每日剂量为3毫克的利拉鲁肽（或最大耐受剂量）或安慰剂，并接受生活方式干预。第56周达到了主要终点，即体重指数（BMI）与基线相比的百分比变化：利拉鲁肽组的平均BMI百分比变化为-5.8%，而安慰剂组为1.6%（95% CI -11.6至-3.2，P< 0.001）。次要终点是体重指数下降至少 5%，接受利拉鲁肽治疗的儿童中 46%、安慰剂组中 9%（调整后的几率比 6.3，95% CI 1.4-28.8，P = 0.02）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Liraglutide treatment in children with obesity

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews Gastroenterology &Hepatology 医学-胃肠肝病学

CiteScore

52.30

自引率

0.60%

发文量

147

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Gastroenterology & Hepatology aims to serve as the leading resource for Reviews and commentaries within the scientific and medical communities it caters to. The journal strives to maintain authority, accessibility, and clarity in its published articles, which are complemented by easily understandable figures, tables, and other display items. Dedicated to providing exceptional service to authors, referees, and readers, the editorial team works diligently to maximize the usefulness and impact of each publication. The journal encompasses a wide range of content types, including Research Highlights, News & Views, Comments, Reviews, Perspectives, and Consensus Statements, all pertinent to gastroenterologists and hepatologists. With its broad scope, Nature Reviews Gastroenterology & Hepatology ensures that its articles reach a diverse audience, aiming for the widest possible dissemination of valuable information. Nature Reviews Gastroenterology & Hepatology is part of the Nature Reviews portfolio of journals.